Generate Investment Management Ltd Sells 17,233 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Generate Investment Management Ltd trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 74.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,767 shares of the biopharmaceutical company’s stock after selling 17,233 shares during the quarter. Generate Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $4,373,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $26,000. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $26,000. Armstrong Advisory Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $22.82 during mid-day trading on Wednesday, hitting $775.94. The company’s stock had a trading volume of 332,608 shares, compared to its average volume of 819,578. The firm has a 50-day moving average price of $790.91 and a 200 day moving average price of $720.73. The stock has a market capitalization of $79.89 billion, a price-to-earnings ratio of 19.17, a PEG ratio of 1.38 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $564.00 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned $12.81 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 3,946 shares of company stock valued at $3,302,458. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on REGN. Leerink Partners upped their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. Finally, Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $834.24.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.